Yuefei Yu

627 citations
29 papers · 476 indexed · h-index 14
Topics
Immunotherapy and Immune Responses (13 papers)Glycosylation and Glycoproteins Research (7 papers)Galectins and Cancer Biology (7 papers)
Partner nations
United StatesItalyChina

In The Last Decade

Yuefei Yu

29 papers receiving 469 citations

Peers

Yuefei Yu
Comparison fields: 5 of 78
  • Molecular Biology 266
  • Immunology 236
  • Oncology 120
  • Pulmonary and Respiratory Medicine 45
  • Cancer Research 45
Replace Paula Ramos Viacava with:
Paula Ramos Viacava Brazil
Morteza Abouzaripour Iran
Kathryn A. Saraf United States
Ivan H. Chan United States
M. Watanabe Japan
Yukun Li China
Karen Madara United States
Xiaoyin Lu China
Rupert Negus United Kingdom
Xuelian Hu China
Yuefei Yu relative to Paula Ramos Viacava Brazil Paula Ramos Viacava's profile →
Citations per field
00.5×
Paula Ramos Viacava · 1×
Citations per year

Countries citing papers authored by Yuefei Yu

Since Specialization
Citations

This map shows the geographic impact of Yuefei Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuefei Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuefei Yu more than expected).

Fields of papers citing papers by Yuefei Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuefei Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuefei Yu. The network helps show where Yuefei Yu may publish in the future.

Co-authorship network of co-authors of Yuefei Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Yuefei Yu. A scholar is included among the top collaborators of Yuefei Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuefei Yu. Yuefei Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 31
2 15
3 24
4 70
5 42
6 1
7 9
8 6
9 1
10 18
11 1
12 40
13 48
14 13
15 41
16 18
17 14
18 16
19 8
20 14

About Yuefei Yu

Yuefei Yu is a scholar working on Immunology, Hematology and Reproductive Medicine, having authored 29 papers that have together received 476 indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (13 papers), Glycosylation and Glycoproteins Research (7 papers) and Galectins and Cancer Biology (7 papers). The work is most often cited by research in Immunology (236 citations), Neuropsychology and Physiological Psychology (8 citations) and Reproductive Medicine (41 citations). Yuefei Yu has collaborated with scholars based in United States, Italy and China. Frequent co-authors include Everardo Cobos, Maurizio Chiriva‐Internati, Marjorie Jenkins, Leonardo Mirandola, Martin J. Cannon, W. Martin Kast, Lei Deng, Qifan Yang, Constance M. John and Guorong Li. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Immunology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026